Suzanne M McCluskey1, Yap Boum, Nicholas Musinguzi, Jessica E Haberer, Jeffrey N Martin, Peter W Hunt, Vincent C Marconi, David R Bangsberg, Mark J Siedner. 1. *Department of Medicine, Massachusetts General Hospital, Boston, MA; †Epicentre Mbarara Research Centre, Mbarara, Uganda; ‡Mbarara University of Science and Technology, Mbarara, Uganda; §Harvard Medical School, Boston, MA; Departments of ‖Epidemiology and Biostatistics; ¶Medicine, University of California San Francisco School of Medicine, San Francisco, CA; #Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA; and **Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA.
Abstract
BACKGROUND: The World Health Organization defines HIV virologic failure as 2 consecutive viral loads >1000 copies/mL, measured 3-6 months apart, with interval adherence support. We sought to empirically evaluate these guidelines using data from an observational cohort. SETTING: The Uganda AIDS Rural Treatment Outcomes study observed adults with HIV in southwestern Uganda from the time of antiretroviral therapy (ART) initiation and monitored adherence with electronic pill bottles. METHODS: We included participants on ART with a detectable HIV RNA viral load and who remained on the same regimen until the subsequent measurement. We fit logistic regression models with viral resuppression as the outcome of interest and both initial viral load level and average adherence as predictors of interest. RESULTS: We analyzed 139 events. Median ART duration was 0.92 years, and 100% were on a nonnucleoside reverse-transcriptase inhibitor-based regimen. Viral resuppression occurred in 88% of those with initial HIV RNA <1000 copies/mL and 42% if HIV RNA was >1000 copies/mL (P <0.001). Adherence after detectable viremia predicted viral resuppression for those with HIV RNA <1000 copies/mL (P = 0.011) but was not associated with resuppression for those with HIV RNA >1000 copies/mL (P = 0.894; interaction term P = 0.077). CONCLUSIONS: Among patients on ART with detectable HIV RNA >1000 copies/mL who remain on the same regimen, only 42% resuppressed at next measurement, and there was no association between interval adherence and viral resuppression. These data support consideration of resistance testing to help guide management of virologic failure in resource-limited settings.
BACKGROUND: The World Health Organization defines HIV virologic failure as 2 consecutive viral loads >1000 copies/mL, measured 3-6 months apart, with interval adherence support. We sought to empirically evaluate these guidelines using data from an observational cohort. SETTING: The Uganda AIDS Rural Treatment Outcomes study observed adults with HIV in southwestern Uganda from the time of antiretroviral therapy (ART) initiation and monitored adherence with electronic pill bottles. METHODS: We included participants on ART with a detectable HIV RNA viral load and who remained on the same regimen until the subsequent measurement. We fit logistic regression models with viral resuppression as the outcome of interest and both initial viral load level and average adherence as predictors of interest. RESULTS: We analyzed 139 events. Median ART duration was 0.92 years, and 100% were on a nonnucleoside reverse-transcriptase inhibitor-based regimen. Viral resuppression occurred in 88% of those with initial HIV RNA <1000 copies/mL and 42% if HIV RNA was >1000 copies/mL (P <0.001). Adherence after detectable viremia predicted viral resuppression for those with HIV RNA <1000 copies/mL (P = 0.011) but was not associated with resuppression for those with HIV RNA >1000 copies/mL (P = 0.894; interaction term P = 0.077). CONCLUSIONS: Among patients on ART with detectable HIV RNA >1000 copies/mL who remain on the same regimen, only 42% resuppressed at next measurement, and there was no association between interval adherence and viral resuppression. These data support consideration of resistance testing to help guide management of virologic failure in resource-limited settings.
Authors: Sheri D Weiser; Alexander C Tsai; Reshma Gupta; Edward A Frongillo; Annet Kawuma; Jude Senkungu; Peter W Hunt; Nneka I Emenyonu; Jennifer E Mattson; Jeffrey N Martin; David R Bangsberg Journal: AIDS Date: 2012-01-02 Impact factor: 4.177
Authors: Jessica E Haberer; Nicholas Musinguzi; Yap Boum; Mark J Siedner; A Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731
Authors: Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo Journal: Antimicrob Agents Chemother Date: 2014-04-14 Impact factor: 5.191
Authors: Jessica E Haberer; Julius Kiwanuka; Denis Nansera; Kathleen Ragland; Claude Mellins; David R Bangsberg Journal: PLoS One Date: 2012-05-09 Impact factor: 3.240
Authors: Pieter W Smit; Kimberly A Sollis; Susan Fiscus; Nathan Ford; Marco Vitoria; Shaffiq Essajee; David Barnett; Ben Cheng; Suzanne M Crowe; Thomas Denny; Alan Landay; Wendy Stevens; Vincent Habiyambere; Joseph H Perriens; Rosanna W Peeling Journal: PLoS One Date: 2014-03-06 Impact factor: 3.240
Authors: Jean d'Amour Ndahimana; David J Riedel; Mutagoma Mwumvaneza; Dieudone Sebuhoro; Jean Claude Uwimbabazi; Marthe Kubwimana; Jules Mugabo; Augustin Mulindabigwi; Catherine Kirk; Steve Kanters; Jamie I Forrest; Linda L Jagodzinski; Sheila A Peel; Muhayimpundu Ribakare; Robert R Redfield; Sabin Nsanzimana Journal: Trop Med Int Health Date: 2016-06-13 Impact factor: 2.622
Authors: Caitlin M Dugdale; Andrea L Ciaranello; Linda-Gail Bekker; Madeline E Stern; Landon Myer; Robin Wood; Paul E Sax; Elaine J Abrams; Kenneth A Freedberg; Rochelle P Walensky Journal: Ann Intern Med Date: 2019-04-02 Impact factor: 25.391
Authors: Paul K Drain; Jienchi Dorward; Andrew Bender; Lorraine Lillis; Francesco Marinucci; Jilian Sacks; Anna Bershteyn; David S Boyle; Jonathan D Posner; Nigel Garrett Journal: Clin Microbiol Rev Date: 2019-05-15 Impact factor: 26.132
Authors: Helen Bell Gorrod; Richard Court; Michael Schomaker; Gary Maartens; Richard A Murphy Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771
Authors: Giovanni Villa; Adam Abdullahi; Dorcas Owusu; Colette Smith; Marilyn Azumah; Laila Sayeed; Harrison Austin; Dominic Awuah; Apostolos Beloukas; David Chadwick; Richard Phillips; Anna Maria Geretti Journal: EClinicalMedicine Date: 2020-01-05
Authors: Rahel E Bircher; Alex J Ntamatungiro; Tracy R Glass; Dorcas Mnzava; Amina Nyuri; Herry Mapesi; Daniel H Paris; Manuel Battegay; Thomas Klimkait; Maja Weisser Journal: PLoS One Date: 2020-01-13 Impact factor: 3.240
Authors: B Nyagadza; N Kudya; E Mbofana; S Masaka; D Garone; C-Y Chen; A Mulingwa; C Uzande; P Isaakidis; Z Ndlovu Journal: Public Health Action Date: 2019-12-21
Authors: Lucas E Hermans; Sergio Carmona; Monique Nijhuis; Hugo A Tempelman; Douglas D Richman; Michelle Moorhouse; Diederick E Grobbee; Willem D F Venter; Annemarie M J Wensing Journal: PLoS Med Date: 2020-02-25 Impact factor: 11.069